PURPOSE: The effect of transient tumor expansion after conventionally fractionated stereotactic radiation therapy (SRT) on the symptomatic outcomes is not well-known. METHODS AND MATERIALS: This study enrolled 201 consecutive patients who received SRT for vestibular schwannoma. A conventional fractionation schedule was applied in 194 patients (97%), and 142 (71%) received a total dose of 50 Gy. The median follow-up time was 72 months. RESULTS: The maximum diameter was 9 mm or less in 13 patients, 10-19 mm in 79 patients, 20-29 mm in 87 patients, and 30 mm or greater in 22 patients. At presentation, tumor size of 20 mm or greater was significantly associated with loss of serviceable hearing and trigeminal neuropathy. After SRT, tumor expansion was observed in 42 patients (21%). By tumor size, tumor expansion was observed in 0%, 11.4%, 25.6%, and 50% of patients with tumors of 9 mm or less, 10-19 mm, 20-29 mm, and 30 mm or greater, respectively, in diameter. The tumor expansion was significantly associated with an increased risk of hydrocephalus requiring shunt placement (P=.004), loss of serviceable hearing (P=.0064), and worsening of facial (P<.0001) and trigeminal nerve (P<.0001) functions. Spontaneous tumor shrinkage was observed in 29 of those 42 patients, mostly within 2 years after the expansion, and the majority of the worsened symptoms except for hearing resolved once the tumor had shrunk. As a result, salvage surgical resection for symptomatic relief was required in only 5% of patients. CONCLUSIONS: Fractionated SRT could be safely applied even for medium- to large-sized (≥20 mm) tumors. However, greater knowledge of the risks and consequences, including transient symptomatic worsening, and the time span of expansion will be required for the follow-up of patients after SRT to avoid unnecessary surgical intervention.
PURPOSE: The effect of transient tumor expansion after conventionally fractionated stereotactic radiation therapy (SRT) on the symptomatic outcomes is not well-known. METHODS AND MATERIALS: This study enrolled 201 consecutive patients who received SRT for vestibular schwannoma. A conventional fractionation schedule was applied in 194 patients (97%), and 142 (71%) received a total dose of 50 Gy. The median follow-up time was 72 months. RESULTS: The maximum diameter was 9 mm or less in 13 patients, 10-19 mm in 79 patients, 20-29 mm in 87 patients, and 30 mm or greater in 22 patients. At presentation, tumor size of 20 mm or greater was significantly associated with loss of serviceable hearing and trigeminal neuropathy. After SRT, tumor expansion was observed in 42 patients (21%). By tumor size, tumor expansion was observed in 0%, 11.4%, 25.6%, and 50% of patients with tumors of 9 mm or less, 10-19 mm, 20-29 mm, and 30 mm or greater, respectively, in diameter. The tumor expansion was significantly associated with an increased risk of hydrocephalus requiring shunt placement (P=.004), loss of serviceable hearing (P=.0064), and worsening of facial (P<.0001) and trigeminal nerve (P<.0001) functions. Spontaneous tumor shrinkage was observed in 29 of those 42 patients, mostly within 2 years after the expansion, and the majority of the worsened symptoms except for hearing resolved once the tumor had shrunk. As a result, salvage surgical resection for symptomatic relief was required in only 5% of patients. CONCLUSIONS: Fractionated SRT could be safely applied even for medium- to large-sized (≥20 mm) tumors. However, greater knowledge of the risks and consequences, including transient symptomatic worsening, and the time span of expansion will be required for the follow-up of patients after SRT to avoid unnecessary surgical intervention.
Authors: Kunal S Patel; Edwin Ng; Taranjit Kaur; Tyler Miao; Tania Kaprealian; Percy Lee; Nader Pouratian; Michael T Selch; Antonio A F De Salles; Quinton Gopen; Stephen Tenn; Isaac Yang Journal: J Neurooncol Date: 2019-09-24 Impact factor: 4.130
Authors: Anurag Saraf; Luke R G Pike; Kevin H Franck; Nora K Horick; Beow Y Yeap; Barbara C Fullerton; Irene S Wang; Mohamed E Abazeed; Michael J McKenna; William A Mehan; Scott R Plotkin; Jay S Loeffler; Helen A Shih Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315
Authors: Michael Huo; Heath Foley; Mark Pinkham; Mihir Shanker; Anne Bernard; Michael Jenkins; Sarah Olson; Bruce Hall; Trevor Watkins; Catherine Jones; Matthew Foote Journal: J Radiosurg SBRT Date: 2020
Authors: May N Tsao; Arjun Sahgal; Wei Xu; Antonio De Salles; Motohiro Hayashi; Marc Levivier; Lijun Ma; Roberto Martinez; Jean Régis; Sam Ryu; Ben J Slotman; Ian Paddick Journal: J Radiosurg SBRT Date: 2017
Authors: Patrick P J H Langenhuizen; Sander H P Sebregts; Svetlana Zinger; Sieger Leenstra; Jeroen B Verheul; Peter H N de With Journal: Med Phys Date: 2020-02-18 Impact factor: 4.071
Authors: Kathryn R Fega; Geoffrey P Fletcher; Mark R Waddle; Jennifer L Peterson; Jonathan B Ashman; David M Barrs; Bernard R Bendok; Naresh P Patel; Alyx B Porter; Sujay A Vora Journal: Adv Radiat Oncol Date: 2018-08-23